Cascade BioSciences Inc.
TSX: CSBXMid-cap oncology developer. Lead candidate CSB-204 in Phase II. Disclosure quality has deteriorated across the last two reporting cycles.
Shell & reverse-merger risk profile
0 of 5 structural risk indicators triggered.
Shared registered office with another reporting issuer
Registered office is unique within the corpus.
Frequent name changes (≥2 in 10 years)
Stable corporate identity.
Director overlap with other monitored issuers
No cross-issuer directorships detected.
Capital pool / shell structural profile
Market cap 612.8M; size profile consistent with shell-stage issuers.
Pivot between unrelated sectors
No unrelated-sector pivots detected.